Verona Pharma plc Verona Pharma Plc: 2017 Annual Report And Accounts And Notice Of Agm

 
TIDMVRP 
 
 
   March 9, 2018, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) 
("Verona Pharma"), a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for respiratory 
diseases, is pleased to confirm that a hard copy of the Annual Report 
and Accounts for the year ended 31 December 2017 ("2017 Annual Report 
and Accounts"), the Notice of Annual General Meeting and a Form of Proxy 
have been posted to Shareholders. 
 
   The Company confirms that a copy of its 2017 Annual Report and Accounts 
and Notice of Annual General Meeting are available online at 
www.veronapharma.com. The Notice of Annual General Meeting can also be 
found within the AIM Rule 26 section of the website. 
 
   The Annual General Meeting of Verona Pharma will be held at the London 
offices of Nasdaq, Woolgate Exchange, 25 Basinghall Street, London EC2V 
5HA at 9.00 a.m. on 2 May 2018. 
 
   -Ends- 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual 
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a 
bronchodilator and an anti-inflammatory agent in a single compound. In 
clinical trials, treatment with RPL554 has been observed to result in 
statistically significant improvements in lung function as compared to 
placebo, and has shown clinically meaningful and statistically 
significant improvements in lung function when administered in addition 
to frequently used short- and long-acting bronchodilators as compared to 
such bronchodilators administered as a single agent. Verona Pharma is 
developing RPL554 for the treatment of chronic obstructive pulmonary 
disease (COPD), cystic fibrosis (CF), and potentially asthma. 
 
   For further information, please contact: 
 
   Verona Pharma plc 
 
   Tel: +44 (0)20 3283 4200 
 
   Jan-Anders Karlsson, Chief Executive Officer 
 
   info@veronapharma.com 
 
 
 
 
 
 
Stifel Nicolaus Europe Limited (Nominated Adviser 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
   Tel: +44 (0) 20 7710 7600 
 
   SNELVeronaPharma@stifel.com 
 
   FTI Consulting (UK Media and Investor enquiries) 
 
   Tel: +44 (0)20 3727 1000 
 
   Simon Conway / Natalie Garland-Collins 
 
   veronapharma@fticonsulting.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/

(END) Dow Jones Newswires

March 09, 2018 12:30 ET (17:30 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024